The PI3K AKT pathway in the pathogenesis of prostate cancer
The DOI matches its Crossref record.
Abstract
Despite recent advances in our understanding of the biological behavior of prostate cancer (PCa), PCa is becoming the most common malignancy in men worldwide. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been implicated in prostate carcinogenesis. Inflammatory cytokines (CCR9, IL-6, and TLR3) regulate PI3K/AKT signaling during apoptosis of PCa cells, and PI3K/AKT signaling participates with androgen-, 1alpha,25(OH)2-vitamin D3-, and prostaglandin-associated mechanisms and is regulated by ErbB, EGFR, and the HER family during cell growth. During metastasis of PCa cells, the PI3K/AKT/NF-kappaB/BMP-2-Smad axis, PTEN/PI3K/AKT pathway, and PI3K/AKT/mTOR signaling regulates tumor cell metastasis and invasion. The present review focuses on the PI3K/AKT signal pathway and discusses the role of the PI3K/AKT signal pathway in PCa tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PI3K/AKT signaling axis is critical in the tumorigenic process of PCa, influencing apoptosis, proliferation, metastasis, and invasion.”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [34]
Citations
Cites
Still being checked.
Cited by
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
Stanciu, S., Radu, F. I., Ștefani, C., Miricescu, D., Stănescu-Spînu, I.-I., Greabu, M., Totan, A., & Jinga, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710132 · Cited by 155
Zhao, X., Wang, J., Deng, Y., Liao, L., Zhou, M., Peng, C. Y., & Li, Y. (2021) · Phytotherapy Research · doi:10.1002/ptr.7104 · Cited by 132
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer
Jiménez‐Vacas, J. M., Herrero‐Aguayo, V., Montero‐Hidalgo, A. J., Gómez‐Gómez, E., Fuentes-Fayos, A. C., León‐González, A. J., Sáez-Martínez, P., Alors‐Pérez, E., Pedraza‐Arévalo, S., González-Serrano, T., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.008 · Cited by 111
Li, B., Xu, W., Lam, A. K.-Y., Wang, Y., Hu, H., Guan, X., Qin, Y., Saremi, N., Tsao, S. W., He, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16333 · Cited by 119
Sex and Gender Influences on Cancer Immunotherapy Response
Irelli, A., Sirufo, M. M., D’Ugo, C., Ginaldi, L., & Martinis, M. D. (2020) · Biomedicines · doi:10.3390/biomedicines8070232 · Cited by 120
Lu, X., Chen, D., Yang, F., & Xing, N. (2020) · Cancer Management and Research · doi:10.2147/cmar.s241093 · Cited by 104
Yu, Y., Guo, J., & Shao, Z. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.09.011 · Cited by 99
Xue, X., Deng, Y., Wang, J., Zhou, M., Liao, L., Wang, C., Peng, C. Y., & Li, Y. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153694 · Cited by 112
MEF2 signaling and human diseases
Chen, X., Gao, B., Ponnusamy, M., Lin, Z., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22899 · Cited by 103
SNAIL1: Linking Tumor Metastasis to Immune Evasion
Tang, X., Sui, X., Weng, L., & Liu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724200 · Cited by 89
Ashrafizadeh, M., Dai, J., Torabian, P., Nabavi, N., Aref, A. R., Aljabali, A. A. A., Tambuwala, M. M., & Zhu, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05236-w · Cited by 95
Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer
Jiménez‐Vacas, J. M., Herrero‐Aguayo, V., Gómez‐Gómez, E., León‐González, A. J., Sáez-Martínez, P., Alors‐Pérez, E., Fuentes-Fayos, A. C., Martínez-López, A., Sánchez‐Sánchez, R., González-Serrano, T., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.001 · Cited by 84
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 91
Chen, L., Xu, Y.-X., Wang, Y., Ren, Y.-Y., Dong, X.-M., Wu, P., Xie, T., Zhang, Q., & Zhou, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02137-1 · Cited by 92
Singh, M., Agarwal, V., Pancham, P., Jindal, D., Agarwal, S., Rai, S., Singh, S., & Gupta, V. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s445130 · Cited by 87
Zhang, L., Sha, J., Yang, G., Huang, X., Bo, J., & Huang, Y. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1312237 · Cited by 69
Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN
Deng, W., Han, W., Fan, T., Wang, X., Cheng, Z., Wan, B., & Chen, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.127 · Cited by 64
Sun, T., Bi, F., Liu, Z., & Yang, Q. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02781-x · Cited by 81
Moon, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052911 · Cited by 76
Wang, W., Zheng, L., Xu, L., Tu, J., & Gu, X. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00179-x · Cited by 62
Jiang, W., Kai, J., Li, D., Wei, Z., Wang, Y., & Wang, W. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29618 · Cited by 59
A review: Pharmacology and pharmacokinetics of Schisandrin A
Fu, K., Zhou, H., Wang, C., Gong, L., Ma, C., Zhang, Y., & Li, Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7456 · Cited by 65
Li, X., Guo, S., Min, L., Guo, Q., & Zhang, S. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4258 · Cited by 61
RetractedmiR-424-5p Promotes Proliferation, Migration and Invasion of Laryngeal Squamous Cell Carcinoma
Li, Y., Liu, J., Hu, W., Zhang, Y., Sang, J., Li, H., Ma, T., Bo, Y., Bai, T., Guo, H., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224325 · Cited by 59
Lin, Y., Chen, F., Shen, L., Tang, X., Du, C., Sun, Z., Ding, H., Chen, J., & Shen, B. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1506-7 · Cited by 53
Hussein, M. A., Valinezhad, K., Adel, E., & Munirathinam, G. (2024) · Cancers · doi:10.3390/cancers16010234 · Cited by 55
Plasma microRNA signature is associated with risk stratification in prostate cancer patients
Al-Qatati, A., Akrong, C., Stevic, I., Pantel, K., Awe, J. A., Saranchuk, J. W., Drachenberg, D., Mai, S., & Schwarzenbach, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.30815 · Cited by 50
Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety
Kuznietsova, H. M., Dziubenko, N., Byelinska, I. V., Hurmach, V. V., Bychko, A., Lynchak, O. V., Milokhov, D. S., Khilya, O. V., & Rybalchenko, V. K. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1703189 · Cited by 49
Development of Clioquinol Platinum(IV) Conjugates as Autophagy-Targeted Antimetastatic Agents
Zhang, M., Li, L., Li, S., Liu, Z., Zhang, N., Sun, B., Wang, Z., Jia, D., Liu, M., & Wang, Q. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01895 · Cited by 47
PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Park, S., Kim, Y. S., Kim, D. Y., So, I., & Jeon, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.001 · Cited by 47
Wang, J., Li, T., Wang, C., Li, S., Luo, Y., Piao, X., Feng, Y., Zhang, Y., Xu, W., Zhang, Y., et al. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01763-7 · Cited by 48
Understanding the Contribution of Lactate Metabolism in Cancer Progress: A Perspective from Isomers
Cai, M., Wan, J., Cai, K., Song, H., Wang, Y., Sun, W., & Hu, J. (2022) · Cancers · doi:10.3390/cancers15010087 · Cited by 50
Zhou, Y., Gu, P., Li, J., Li, F., Zhu, J., Gao, P., Zang, Y., Wang, Y., Shan, Y., & Yang, D. (2017) · Oncology Reports · doi:10.3892/or.2017.5961 · Cited by 45
Zeng, Y., & Yang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8653 · Cited by 44
RetractedLi, C., Feng, S., & Chen, L. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03937-x · Cited by 43
Ye, M., Tian, H., Lin, S., Mo, J., Li, Z., Chen, X., & Liu, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12032 · Cited by 46
Exosomal Noncoding RNAs and Tumor Drug Resistance
Guo, C., Liu, J., Zhou, Q., Song, J., Zhang, Z., Li, Z., Wang, G., Yuan, W., & Sun, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0032 · Cited by 45
Yao, M., Li, R., Yang, Z., Ding, Y., Zhang, W., Li, W., Liu, M., Zhao, C., Wang, Y., Tang, H., et al. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109246 · Cited by 41
Artesunate ameliorates sepsis-induced acute lung injury by activating the mTOR/AKT/PI3K axis
Zhang, E., Wang, J., Chen, Q., Wang, Z., Li, D., Jiang, N., & Ju, X. (2020) · Gene · doi:10.1016/j.gene.2020.144969 · Cited by 40
Ye, J., Gao, M., Guo, X., Zhang, H., & Jiang, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110223 · Cited by 39
Zhuang, S., Li, L., Zang, Y., Li, G., & Wang, F. (2020) · Oncology Letters · doi:10.3892/ol.2020.11428 · Cited by 46
Zhao, Y., Cai, J., Shi, K., Li, H., Du, J., Hu, D., Liu, Z., & Wang, W. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12091 · Cited by 42
Zhang, X., Wang, D., Liu, B., Jin, X., Wang, X., Pan, J., Tu, W., & Shao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01657-0 · Cited by 41
RetractedGui, F., Hong, Z., You, Z., Wu, H., & Zhang, Y. (2016) · Cell Biology International · doi:10.1002/cbin.10678 · Cited by 37
BMP signaling in cancer stemness and differentiation
Zhou, W. Z., Yan, K. H., & Xi, Q. (2023) · Cell Regeneration · doi:10.1186/s13619-023-00181-8 · Cited by 41
Chronic stress promotes glioma cell proliferation via the PI3K/Akt signaling pathway
Zhang, Z., Wang, X., Xue, B.-H., Zhao, Y. F., Xie, F., Wang, S.-D., Xue, C., Wang, Y., Zhang, Y., & Qian, L. (2021) · Oncology Reports · doi:10.3892/or.2021.8153 · Cited by 40
Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis
Chen, J., Sun, J., Wang, Q., Du, Y., Cheng, J., Yi, J., Xie, B., Jin, S., Chen, G., Wang, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.825484 · Cited by 35
FTY720 in CNS injuries: Molecular mechanisms and therapeutic potential
Zhang, L., & Wang, H. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.08.013 · Cited by 33
Cui, S. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24761 · Cited by 34
Xiao, Z., Peng, J., Gan, N., Arafat, A., & Yin, F. (2016) · NeuroImmunoModulation · doi:10.1159/000460254 · Cited by 38
STC1 promotes cell apoptosis via NF-κB phospho-P65 Ser536 in cervical cancer cells
Pan, X., Jiang, B., Liu, J., Ding, J., Li, Y., Sun, R., Peng, L., Qin, C., Fang, S., & Li, G. (2017) · Oncotarget · doi:10.18632/oncotarget.17641 · Cited by 36
Complex Systems Biology Approach in Connecting PI3K-Akt and NF-κB Pathways in Prostate Cancer
Shankar, E., Weis, M. C., Avva, J., Shukla, S., Shukla, M., Sreenath, S. N., & Gupta, S. (2019) · Cells · doi:10.3390/cells8030201 · Cited by 42
Ma, R., Zhu, P., Liu, S., Gao, B., & Wang, W. T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.046 · Cited by 33
Sun, W., Zhang, N.-D., Zhang, T., Li, Y., Xue, H. Y., Cao, J., Hou, W.-S., Liu, J., Wang, Y., & Jin, C. (2023) · Molecules · doi:10.3390/molecules28020652 · Cited by 36
Chang, M., Zhu, D., Chen, Y., Zhang, W., Liu, X., Li, X.-L., Cheng, Z., Su, Z., Zhang, J., Lü, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.758219 · Cited by 32
Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis
Kumar, N., & Mandal, C. C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.724149 · Cited by 32
Role of androgen receptor splice variants, their clinical relevance and treatment options
Wach, S., Taubert, H. W., & Cronauer, M. V. (2019) · World Journal of Urology · doi:10.1007/s00345-018-02619-0 · Cited by 34
Gao, H., Ren, Y., & Liu, C. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9697887 · Cited by 31
MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities
Syed, R. U., Banu, H., Alshammrani, A., Alshammari, M. D., Satheesh Kumar, G., Kadimpati, K. K., Khalifa, A. A. S., Aboshouk, N. A. M., Almarir, A. M., Hussain, A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155572 · Cited by 41
Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer
Lounis, M. A., Péant, B., Leclerc-Desaulniers, K., Ganguli, D., Daneault, C., Ruiz, M., Zoubeidi, A., Mes‐Masson, A., & Fred Saad, C. (2020) · Cancers · doi:10.3390/cancers12113339 · Cited by 30
Huang, K., & Tang, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03455-8 · Cited by 29
Li, J., Zhang, Z., Hu, J.-T., Wan, X., Huang, W., Zhang, H., & Jiang, N. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04290-3 · Cited by 32
Resveratrol Downregulates miR‐155‐5p to Block the Malignant Behavior of Gastric Cancer Cells
Su, N., Li, L., Zhou, E., Li, H., Wu, S., & Cao, Z. (2022) · BioMed Research International · doi:10.1155/2022/6968641 · Cited by 30
Li, Z., Zhang, C., Wang, L., Zhang, Q., Dong, Y., Sha, X., Wang, B., Zhu, Z., Wang, W., Wang, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84398-w · Cited by 33
Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
Hao, X., Gao, L., Deng, X., Han, F., Chen, H., JIANG, X. H., Liu, W., Wang, D., Chen, J.-P., Cui, Z.-H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1663-5 · Cited by 31
Gao, X., & Yang, J. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5088 · Cited by 28
Liu, C., Xing, W., Yu, H., Zhang, W., & Si, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01800-7 · Cited by 29
Azhati, B., Reheman, A., Dilixiati, D., & Rexiati, M. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109604 · Cited by 28
Regulatory effects of statins on Akt signaling for prevention of cancers
Hosseini, F. S., Ahmadi, A., Kesharwani, P., Hosseini, H., & Sahebkar, A. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111213 · Cited by 30
Xiao, Z., Peng, J., Wu, L., Arafat, A., & Yin, F. (2017) · Neurological Research · doi:10.1080/01616412.2017.1312070 · Cited by 29
Zhang, L., Mao, L., & Wang, H. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03028-6 · Cited by 28
AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
Fu, Y., Cao, T., Zou, X., Ye, Y., Liu, Y., Peng, Y., Deng, T., Yin, L., & Li, X. (2023) · Oncogenesis · doi:10.1038/s41389-022-00446-y · Cited by 27
Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer
Liu, J., Gu, X., Guan, Z., Huang, D., Xing, H., & Lian, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04651-0 · Cited by 28
Bai, M., He, C., Shi, S., Wang, M., Ma, J., Yang, P., Dong, Y., Mou, X., & Han, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.636965 · Cited by 26
Chen, G., Liu, X., Chen, J., Yu, X., Luo, J., Yan, Z.-R., & Tao, Q. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5233462 · Cited by 29
Constitutively Active Androgen Receptor in Hepatocellular Carcinoma
Montgomery, E. J., Xing, E., Campbell, M. J., Li, P., Blachly, J. S., Tsung, A., & Coss, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213768 · Cited by 25
Lei, Y., Chan, M.-C., Liu, H., Lyu, W.-Y., Chen, L., Zhong, Y., Gan, H., Wang, M., Qi, M., Guo, Y. L., et al. (2022) · Disease Markers · doi:10.1155/2022/4399334 · Cited by 24
B7-H4 is a potential prognostic biomarker of prostate cancer
Li, H., Piao, L., Liu, S., Cui, Y. R., & Xuan, Y. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104406 · Cited by 26
Scutellarin Inhibits the Growth and EMT of Gastric Cancer Cells through Regulating PTEN/PI3K Pathway
Fu, L., Wang, S., & Niu, M. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00822 · Cited by 24
Sodium Danshensu inhibits the progression of lung cancer by regulating PI3K /Akt signaling pathway
Wang, M., Tang, W., Gong, N., & Liu, P. (2021) · Drug Development Research · doi:10.1002/ddr.21846 · Cited by 24
Tai, S., Xu, L., Xu, M., Zhang, L., Zhang, Y., Zhang, K., Zhang, L., & Liang, C. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14493 · Cited by 24
MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27
Ding, J., Sha, L., Shen, P., Huang, M., Cai, Q., & Li, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4374 · Cited by 24
miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2
Cao, H., Liu, Z., Wang, R., Zhang, X., Yi, W., Nie, G., Yu, Y., Wang, G., & Zhu, M. (2016) · Oncology Reports · doi:10.3892/or.2016.5257 · Cited by 23
RetractedLi, T., Si, W., Zhu, J., Li, Y., & Zhong, C. (2020) · PubMed Central · Cited by 23
Chen, X., Tian, F., Lun, P., & Feng, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5574555 · Cited by 23
Sanmukh, S. G., dos Santos, N. J., Barquilha, C. N., Cucielo, M. S., de Carvalho, M., Reis, P. P., Delella, F. K., Carvalho, H. F., & Felisbino, S. L. (2021) · Viruses · doi:10.3390/v13091754 · Cited by 24
Li, X., Hua, Y., Yang, C., Liu, S., Tan, L., Guo, J., & Yang, L. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03925-w · Cited by 23
Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer
Lu, L., Cole, A. I., Huang, D., Wang, Q., Guo, Z., Yang, W., & Lu, J. Z. (2022) · Biomolecules · doi:10.3390/biom12020203 · Cited by 21
Ge, J., Wang, P., Ma, H., & Zhang, J. (2022) · Journal of Oncology · doi:10.1155/2022/9055954 · Cited by 23
Molecular docking analysis of lupeol with different cancer targets
Gunasekaran, M. (2022) · Bioinformation · doi:10.6026/97320630018134 · Cited by 21
Liu, S., Hu, J., Shi, C., Sun, L., Yan, W., & Yong-sheng, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16560 · Cited by 22
Wang, R., Wen, P., Yang, G., Feng, Y., Mi, Y., Wang, X., Zhu, S., & Chen, Y. Q. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05090-3 · Cited by 20
Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression
Lazniewska, J., Li, K.-L., Johnson, I. R. D., Sorvina, A., Logan, J. M., Martini, C., Moore, C. R., Ung, B., Karageorgos, L., Hickey, S. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40347-7 · Cited by 19
Utter, M., Chakraborty, S., Goren, L., Feuser, L., Zhu, Y., & Foster, D. A. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.006 · Cited by 20
Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance
Wang, Z., Wang, J., Li, D., Wu, R., Huang, J., Ye, L., Tuo, Z., Yu, Q., Shao, F., Wusiman, D., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101232 · Cited by 24
Anti-Cancer Mechanisms of Taurine in Human Nasopharyngeal Carcinoma Cells
He, F., Ma, N., Midorikawa, K., Hiraku, Y., Oikawa, S., Mo, Y., Zhang, Z., Takeuchi, K., & Murata, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8023-5_49 · Cited by 22
The role of cyclins in the development and progression of prostate cancer
Dulińska-Litewka, J., Felkle, D., Dykas, K., Handziuk, Z., Krzysztofik, M., & Gąsiorkiewicz, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113742 · Cited by 27
Long non‑coding RNAs in prostate tumorigenesis and therapy (Review)
Jiang, G., SU, Z., Liang, X., Huang, Y., Lan, Z., & Jiang, X. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2146 · Cited by 20
Kou, L., Wei, S., & Kou, P. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.733463 · Cited by 22
Metadata
- Authors
- Wen, X.
- Affiliations
- Shanghai East Hospital (CN)
- Corresponding author
- Wen, Xiaofei
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2016
- Volume
- 21
- Issue
- 5
- Pages
- 1084-1091
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/4443
- OpenAlex
- W2328671688
- Cited by
- 283
- References
- 0
- Citations by year
- 2026: 10 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 45 · 2021: 41 · 2020: 29 · 2019: 17 · 2018: 11 · 2017: 9 · 2016: 4
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Frontiers in bioscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- prostate cancer, PI3K/Akt signaling, prostate carcinogenesis, metastasis, tumor invasion, NF-κB, PTEN, mTOR signaling, androgen signaling, vitamin D3, prostaglandins, EGFR, HER family, inflammatory cytokines, apoptosis
- MeSH terms
- Humans, Male, Neoplasm Invasiveness, Neoplasm Metastasis, Prostatic Neoplasms, Signal Transduction, Apoptosis, Cell Proliferation, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.